Recent advances in oncolytic adenovirus therapies for cancer

Area of Science:

• Oncolytic virotherapy
• Cancer gene therapy
• Adenovirus vector engineering

Background:

• Oncolytic adenoviruses (Onc.Ads) selectively infect and lyse cancer cells, making them valuable tools in cancer gene therapy clinical trials.
• While effective, Onc.Ads alone often fail to eradicate tumors due to the complex and hostile tumor microenvironment.
• Tumors possess structural and immune-evasion mechanisms that impede efficient oncolytic virotherapy.

Purpose of the Study:

• To explore the potential of genetically modified oncolytic adenoviruses (Onc.Ads) for enhanced cancer treatment.
• To investigate strategies for overcoming physical and immunological barriers presented by solid tumors.
• To evaluate the combination of oncolysis with tumor microenvironment modulation for improved Ad-based cancer gene therapy.

Main Methods:

• Genetic modification of adenoviral vectors to enhance tropism and replication in specific cancer cells.
• Engineering "Armed Onc.Ads" to deliver therapeutic molecules targeting tumor microenvironment barriers.
• Investigating the synergistic effects of oncolysis and tumor microenvironment modulation.

Main Results:

• Oncolytic adenoviruses demonstrate selective replication and lysis of cancer cells.
• Genetic modifications can tailor Onc.Ad tropism and replication.
• Armed Onc.Ads are designed to overcome tumor-associated physical and immunological defenses.
• Combining oncolysis with microenvironment targeting shows promise for Ad-based cancer therapy.

Conclusions:

• Oncolytic adenoviruses are a promising platform for cancer gene therapy.
• Genetic engineering of Onc.Ads can improve their efficacy by targeting specific cancer cells.
• Armed Onc.Ads represent a strategy to overcome tumor microenvironment barriers.
• The combination of oncolysis and tumor microenvironment modulation offers a potent approach for Ad-based cancer treatment.